JP2022532850A5 - - Google Patents

Info

Publication number
JP2022532850A5
JP2022532850A5 JP2021563175A JP2021563175A JP2022532850A5 JP 2022532850 A5 JP2022532850 A5 JP 2022532850A5 JP 2021563175 A JP2021563175 A JP 2021563175A JP 2021563175 A JP2021563175 A JP 2021563175A JP 2022532850 A5 JP2022532850 A5 JP 2022532850A5
Authority
JP
Japan
Prior art keywords
pyridine
pyrrolo
tetrahydro
methoxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532850A (ja
JP7641913B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/061176 external-priority patent/WO2020216781A1/en
Publication of JP2022532850A publication Critical patent/JP2022532850A/ja
Publication of JP2022532850A5 publication Critical patent/JP2022532850A5/ja
Application granted granted Critical
Publication of JP7641913B2 publication Critical patent/JP7641913B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563175A 2019-04-24 2020-04-22 4h-ピロロ[3,2-c]ピリジン-4-オン化合物 Active JP7641913B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962838051P 2019-04-24 2019-04-24
US62/838,051 2019-04-24
US201962940036P 2019-11-25 2019-11-25
US62/940,036 2019-11-25
PCT/EP2020/061176 WO2020216781A1 (en) 2019-04-24 2020-04-22 4h-pyrrolo[3,2-c]pyridin-4-one compounds

Publications (3)

Publication Number Publication Date
JP2022532850A JP2022532850A (ja) 2022-07-20
JP2022532850A5 true JP2022532850A5 (cg-RX-API-DMAC7.html) 2023-04-14
JP7641913B2 JP7641913B2 (ja) 2025-03-07

Family

ID=70456765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563175A Active JP7641913B2 (ja) 2019-04-24 2020-04-22 4h-ピロロ[3,2-c]ピリジン-4-オン化合物

Country Status (32)

Country Link
US (2) US12679836B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959211B1 (cg-RX-API-DMAC7.html)
JP (1) JP7641913B2 (cg-RX-API-DMAC7.html)
KR (1) KR102915019B1 (cg-RX-API-DMAC7.html)
CN (3) CN114127064B (cg-RX-API-DMAC7.html)
AU (1) AU2020262221B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019998B1 (cg-RX-API-DMAC7.html)
CA (1) CA3137218A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002770A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014022A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210530A (cg-RX-API-DMAC7.html)
DK (1) DK3959211T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2021000216A (cg-RX-API-DMAC7.html)
EC (1) ECSP21077614A (cg-RX-API-DMAC7.html)
ES (1) ES3068321T3 (cg-RX-API-DMAC7.html)
FI (1) FI3959211T3 (cg-RX-API-DMAC7.html)
GE (2) GEAP202415804A (cg-RX-API-DMAC7.html)
HR (1) HRP20260409T1 (cg-RX-API-DMAC7.html)
IL (1) IL287390B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20210285A1 (cg-RX-API-DMAC7.html)
LT (1) LT3959211T (cg-RX-API-DMAC7.html)
MA (1) MA55751B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021012987A (cg-RX-API-DMAC7.html)
PE (1) PE20220254A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552693A1 (cg-RX-API-DMAC7.html)
PL (1) PL3959211T3 (cg-RX-API-DMAC7.html)
PT (1) PT3959211T (cg-RX-API-DMAC7.html)
RS (1) RS68081B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111304UA (cg-RX-API-DMAC7.html)
TW (1) TWI849114B (cg-RX-API-DMAC7.html)
UA (1) UA130453C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020216781A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CN115836070B (zh) * 2020-08-10 2024-08-09 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
MX2023003362A (es) * 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2022094271A1 (en) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
EP4244225B1 (en) * 2020-11-11 2026-06-03 Bayer Aktiengesellschaft N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl}oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
JP2024517808A (ja) * 2021-05-06 2024-04-23 セルジーン コーポレーション N-((r)-1-(3-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((s)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミドによる治療方法
IL315739A (en) * 2022-03-24 2024-11-01 Scorpion Therapeutics Inc Methods of synthesizing egfr inhibitors
WO2023205595A2 (en) * 2022-04-20 2023-10-26 Celyn Therapeutics, Inc Egfr inhibitors in cancer treatment
CA3270236A1 (en) 2024-08-28 2026-04-10 Bayer Aktiengesellschaft Stable solid pharmaceutical dosage form comprising crystalline form of her2/mutegfr inhibitor and process for its preparation
CA3270230A1 (en) 2024-08-28 2026-04-10 Bayer Aktiengesellschaft Crystalline forms of her2/mutegfr inhibitors and process for their preparation
CN119264091B (zh) * 2024-09-04 2025-05-27 康龙化成手性医药技术(宁波)有限公司 一种1,5-双取代-3-氧杂双环[3.1.1]庚烷的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7211573B2 (en) 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
DE102006033140A1 (de) 2006-07-18 2008-01-24 Merck Patent Gmbh Aminoindazolharnstoffderivate
JP2008291023A (ja) 2007-04-27 2008-12-04 Sumitomo Chemical Co Ltd アミド化合物とその用途
EP2188292B1 (en) 2007-08-08 2013-05-29 GlaxoSmithKline Intellectual Property Development Limited 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer
CN101367801B (zh) 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2976336A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
AR097325A1 (es) 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
SMT202000133T1 (it) 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
US20170166598A1 (en) 2014-05-13 2017-06-15 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
TW201613886A (en) 2014-06-17 2016-04-16 Bayer Pharma AG 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
ES2722431T3 (es) 2014-12-08 2019-08-12 Bayer Pharma AG Novedosos compuestos de aril-cianoguanidina
WO2016100166A1 (en) 2014-12-15 2016-06-23 Bristol-Myers Squibb Company SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS
CN107406417B (zh) * 2015-01-28 2020-06-09 拜耳制药股份公司 4H-吡咯并[3,2-c]吡啶-4-酮衍生物
WO2016185333A1 (en) 2015-05-15 2016-11-24 Novartis Ag Methods for treating egfr mutant cancers
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3137610A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
CA3177214A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer

Similar Documents

Publication Publication Date Title
FI3959211T3 (fi) 4h-pyrrolo[3,2-c]pyridin-4-oniyhdisteitä
JP7493251B2 (ja) ピラゾール置換縮合環誘導体並びにその製造方法及び応用
JP2019510746A5 (cg-RX-API-DMAC7.html)
CN103402519B (zh) 肿瘤治疗剂
JP7732668B2 (ja) 窒素含有多環式縮合環系化合物、その薬学的組成物、製造方法及び用途
JP2024527567A5 (cg-RX-API-DMAC7.html)
JP2022536728A5 (cg-RX-API-DMAC7.html)
JP2023536164A5 (cg-RX-API-DMAC7.html)
JP7227913B2 (ja) 血液悪性腫瘍患者の治療方法
JP2016525076A5 (cg-RX-API-DMAC7.html)
JP2016526540A5 (cg-RX-API-DMAC7.html)
JP2005534669A5 (cg-RX-API-DMAC7.html)
JP2019535744A5 (cg-RX-API-DMAC7.html)
NZ603654A (en) Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
JP2014513110A5 (cg-RX-API-DMAC7.html)
JP2017505790A5 (cg-RX-API-DMAC7.html)
JP2020514292A (ja) 癌の治療に対する併用療法
JP2009504771A5 (cg-RX-API-DMAC7.html)
JP2024515243A5 (cg-RX-API-DMAC7.html)
WO2019045036A1 (ja) エクソン18及び/又はエクソン21変異型egfr選択的阻害剤
CN106255500B (zh) 用于治疗癌症的新的头孢菌素衍生物
JP2024545193A5 (cg-RX-API-DMAC7.html)
JP2024539633A5 (cg-RX-API-DMAC7.html)
JP6908287B2 (ja) 脳腫瘍の処置のための治療剤としての2−アミノピリミジン誘導体
JP2009537606A5 (cg-RX-API-DMAC7.html)